



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmr.org
www.multiplemyeloma.org

February 17, 2009

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Dear Colleague:

Welcome to New York and to the *Multiple Myeloma Research Foundation (MMRF)* and the *Multiple Myeloma Research Consortium (MMRC) 2009 Scientific Agenda Roundtable*.

Our primary objective for this meeting is to refine our Scientific Agenda, the five-year research plan that drives both MMRF and MMRC funding and businesses. This meeting will help us gain insights from both within and outside the field of myeloma R&D in diverse specialties such as genomics, proteomics, drug discovery, validation, and clinical development. As a result of these insights, we will be able to prioritize our areas of focus for 2009 and future years, leading to improved outcomes for patients with myeloma.

We are pleased and honored that you are here. This meeting will feature a distinguished group of scientists who join us in our commitment to help accelerate drug development in myeloma.

Once again, thank you. We look forward to working together today and in future endeavors.

Sincerely,

Louise M. Perkins, PhD
Chief Scientific Officer
Multiple Myeloma Research Foundation

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.

383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org



2009 SCIENTIFIC AGENDA ROUNDTABLE

Sponsored by the **MMRF** and the **MMRC**

LE PARKER MERIDIEN • NEW YORK, NY

Tuesday, February 17, 2009

AGENDA

Founder/CEO

Kathy Giusti

8:00 AM – 9:00 AM

Breakfast

COO/Executive Director

Scott T. Santarella

9:00 AM – 9:30 AM

Welcome and Objectives

MMRF/C

Leadership Council

Lester B. Knight

Philip J. Purcell

Robert Wolf

Introductions

Honorary Board

Dusty Baker

Don Baylor

Bob Costas

Katie Couric

Cindy Crawford

Ann Curry

Geraldine Ferraro

Scott Hamilton

Mariska Hargitay

Bonnie Hunt

Senator Kay Bailey Hutchison

Dan Jansen

Hamilton Jordan

Diana Krall

Eric McCormack

Keith Olbermann

Sharon Osbourne

Deborah Norville

General Norman Schwarzkopf

Mel Stottlemire

Brian Williams

Paula Zahn

9:30 AM – 9:45 AM

Process and Expected Outputs

Louise M. Perkins, PhD

MMRF

Update on MMRF/C Activities

MMRF/C

9:45 AM – 10:45 AM

Background

Drug Development in Myeloma

Kenneth C. Anderson, MD

Dana-Farber Cancer Institute

Harvard Medical School

Update on MMRC Genomics Initiative

Daniel Auclair, PhD

MMRC

Challenges of Oncology Biomarker Development

Nicholas C. Dracopoli, PhD

Centocor R&D, Johnson & Johnson

10:45 AM – 11:00 AM

Break

Board of Directors

Dana LaForge, Chairman

Kenneth C. Anderson, M.D.

Karen Andrews

Robert J. Beall, Ph.D.

Robert B. DeBaun

Mark Fishman

Kathy Giusti

Stephen Grand

Alan L. Heller

Joseph M. Hogan

Anthony K. Kesman

Thomas J. Kipps, M.D.

Lori Marcus

Gerald McDougall

William S. McKiernan

Charles B. Ortner

Alan Panzer

Edward Jay Phillips

Stuart Rosow

William Wilson III

Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.

383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org



2009 SCIENTIFIC AGENDA ROUNDTABLE

Sponsored by the **MMRF** and the **MMRC**

LE PARKER MERIDIEN • NEW YORK, NY

Tuesday, February 17, 2009

AGENDA (CONT)

Founder/CEO Kathy Giusti	11:00 AM – 1:30 PM	Revision of the Scientific Agenda for Myeloma Research
COO/Executive Director Scott T. Santarella	11:00 AM – 1:00 PM	Group Breakout Sessions (includes working lunch) Group Work
Leadership Council Lester B. Knight Philip J. Purcell Robert Wolf	1:00 PM – 1:30 PM	Wrap-up and Slide Preparation
Honorary Board Dusty Baker Don Baylor Bob Costas Katie Couric Cindy Crawford Ann Curry Geraldine Ferraro Scott Hamilton Mariska Hargitay Bonnie Hunt Senator Kay Bailey Hutchison Dan Jansen Hamilton Jordan Diana Krall Eric McCormack Keith Olbermann Sharon Osbourne Deborah Norville General Norman Schwarzkopf Mel Stottlemire Brian Williams Paula Zahn	1:30 PM – 2:30 PM	Working Group Presentations (group co-chairs) New Target/Compound Identification and Validation G. David Roodman, MD, PhD <i>University of Pittsburgh</i> Mark Miglarese, PhD <i>OSI Pharmaceuticals</i> Joan Levy, PhD <i>MMRF</i> Movement Towards Personalized Medicine Kenneth C. Anderson, MD <i>Dana-Farber Cancer Institute</i> <i>Harvard Medical School</i> Nicholas C. Dracopoli, PhD <i>Centocor R&D, Johnson & Johnson</i> Susan Kelley, MD <i>MMRC</i>
Board of Directors Dana LaForge, Chairman Kenneth C. Anderson, M.D. Karen Andrews Robert J. Beall, Ph.D. Robert B. DeBaun Mark Fishman Kathy Giusti Stephen Grand Alan L. Heller Joseph M. Hogan Anthony K. Kesman Thomas J. Kipps, M.D. Lori Marcus Gerald McDougall William S. McKiernan Charles B. Ortner Alan Panzer Edward Jay Phillips Stuart Rosow William Wilson III Donna Zaccaro	2:30 PM – 3:30 PM	Group Discussion and Prioritization of Projects
	3:30 PM – 4:00 PM	Wrap-up and Immediate Next Steps <i>MMRF/C</i>

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

2009 SCIENTIFIC AGENDA ROUNDTABLE

Sponsored by the **MMRF** and the **MMRC**

LE PARKER MERIDIEN • NEW YORK, NY

Tuesday, February 17, 2009

PARTICIPANT LIST – ATTENDEES

Founder/CEO

Kathy Giusti

COO/Executive Director

Scott T. Santarella

Leadership Council

Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Lance Armstrong
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Frederick H. Joseph
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Alex A. Adjei, MD, PhD

Chair, Department of Medicine
Roswell Park Cancer Institute
Elm and Carlton Sts
Buffalo, NY 14263
Phone (716) 845-4101
Fax (716) 845-3423
alex.adjei@roswellpark.org

Kenneth C. Anderson, MD

Chief, Division of Hematologic
Neoplasia
Dana-Farber Cancer Institute
Kraft Family Professor of Medicine
Harvard Medical School
44 Binney St
Room M557
Boston, MA 02115
Phone (617) 632-2144
Fax (617) 632-2140
kenneth_anderson@dfci.harvard.edu

Bart Barlogie, MD, PhD

Professor
University of Arkansas for
Medical Sciences
4301 W Markham St
Slot 816
Little Rock, AR 72205
Phone (501) 526-6990, ext 2421
Fax (501) 526-2273
barlogiebart@uams.edu

Richard Caprioli, PhD

Professor
Vanderbilt University
465 21st Ave S
9160 MRB III
Nashville, TN 37232-8575
Phone (615) 322-4336
Fax (615) 343-8372
r.caprioli@vanderbilt.edu

John D. Carpten, PhD

Senior Investigator & Director
Integrated Cancer Genomics Division
TGen
445 N Fifth St
Ste 500
Phoenix, AZ 85004
Phone (602) 343-8819
Fax (602) 343-8842
jcarpten@tgen.org

Frank L. Douglas, PhD, MD

Senior Fellow
Kauffman Foundation
4801 Rockhill Rd
Kansas City, MO 64110
Phone (816) 932-1204
Fax (816) 751-6813
fdouglas@kauffman.org

Nicholas C. Dracopoli, PhD

Vice President, Biomarkers
Centocor R&D, Johnson & Johnson
145 King of Prussia Rd
Radnor, PA 19087
Phone (610) 889-4762
ndracopo@its.jnj.com

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D.
Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P.
Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D.
Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

PARTICIPANT LIST – ATTENDEES (CONT)

Dixie-Lee Esseltine, MD, FRCPC
Vice President, Global Medical Affairs
Millennium: The Takeda
Oncology Company
40 Lansdowne St
Cambridge, MA 02139
Phone (617) 551-2956
Fax (617) 444-2180
dixie-lee.esseltine@mpi.com

Ellen G. Feigal, MD
Executive Medical Director
Global Development
Amgen, Inc.
One Amgen Center Dr
MS 38-2-A
Thousand Oaks, CA 91320
Phone (805) 447-0286
Fax (805) 480-4978
efeigal@amgen.com

Carl June, MD
Professor of Pathology and
Laboratory Medicine
Director of Translational Research
Programs
University of Pennsylvania
421 Curie Blvd
554 BRB II/III
Philadelphia, PA 19104-6160
Phone (215) 573-5745
Fax (215) 573-8590
cjune@exchange.upenn.edu

Jonathan Keats, PhD
Research Fellow
Mayo Clinic
13400 E Shea Blvd
MCCRB 3-024
Scottsdale, AZ 85259
Phone (480) 301-4709
Fax (480) 301-8387
keats.jonathan@mayo.edu

William Matsui, MD
Associate Professor of Oncology
Johns Hopkins University
1650 Orleans St
Baltimore, MD 21231
Phone (410) 955-2808
Fax (410) 614-7279
matsuwi@jhmi.edu

Mark Miglarese, PhD
Vice President, Translational Research
OSI Pharmaceuticals, Inc.
2860 Wilderness Pl
Boulder, CO 80301
Phone (303) 546-7634
mmiglarese@osip.com

Constantine S. Mitsiades, MD, PhD
Instructor in Medicine
Dana-Farber Cancer Institute
Harvard Medical School
44 Binney St
Mayer Bldg, Room M555
Boston, MA 02115
Phone (617) 632-1962
Fax (617) 812-7701
constantine_mitsiades@dfci.harvard.edu



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board
Lance Armstrong
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Frederick H. Joseph
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

PARTICIPANT LIST – ATTENDEES (CONT)

David Parkinson, MD
President and CEO
Nodality
201 Gateway Blvd
South San Francisco, CA 94080
Phone (650) 827-8035
Fax (650) 827-8001
david.parkinson@nodality.com

Deborah Ricci, PhD
Director, Clinical Research
& Development
Johnson & Johnson
Phone (908) 218-7482
Fax (908) 429-0695
dricci@its.jnj.com

G. David Roodman, MD, PhD
Professor of Medicine
University of Pittsburgh
VA Pittsburgh Healthcare System
Research and Development
151-U University Dr C
Rm 2E114
Pittsburgh, PA 15240
Phone (412) 360-6571
Fax (412) 360-6960
roodmangd@upmc.edu

Nancy Simonian, MD
Chief Medical Officer
Millennium Pharmaceuticals, Inc.
40 Lansdowne St
Cambridge, MA 02139
Phone (617) 551-3612
nancy.simonian@mpi.com

Freda Stevenson, DPhil
Professor
University of Southampton
Cancer Sciences Division
Southampton University
Hospitals Trust
Southampton, S016 6YD
United Kingdom
Phone 011-44-2380-796923
Fax 011-44-2380-795152
fs@soton.ac.uk

Michael Tomasson, MD
Associate Professor
Washington University
600 S Euclid Ave
Campus Box 8056
St. Louis, MO 63110
Phone (314) 362-9350
Fax (314) 362-9333
tomasson@dom.wustl.edu

Richard L. Wahl, MD
Director, Division of Nuclear
Medicine/PET
Johns Hopkins Medicine
601 N Caroline St
Room 3223
Baltimore, MD 21287-0817
Phone (410) 614-3764
Fax (443) 287-2933
rwahl@jhmi.edu

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman
Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D.
Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P.
Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D.
Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

PARTICIPANT LIST – ATTENDEES (CONT)

Jeffrey Wolf, MD

Director, Clinical Research for
Hematology Malignancies
UCSF, Department of Medicine,
Hematology/Oncology
400 Parnassus Ave
Room A502, Box 0324
San Francisco, CA 94143-0324
Phone (415) 353-2737
Fax (415) 353-8205
wolfj@medicine.ucsf.edu

Jerry Zeldis, MD, PhD

Senior Vice President, Clinical
Research & Medical Affairs
Chief Medical Officer
Celgene Corporation
86 Morris Ave
Summit, NJ 07901
Phone (908) 673-9613
Fax (908) 673-2778
jzeldis@celgene.com

PARTICIPANT LIST – MMRF/MMRC

Kathy Giusti

Founder & CEO
Multiple Myeloma Research Foundation
Multiple Myeloma Research Consortium
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0201
Fax (203) 972-1259
giustik@themmrf.org

Louise M. Perkins, PhD

Chief Scientific Officer
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0208
Fax (203) 972-1259
perkinsl@themmrf.org

Susan Kelley, MD

Chief Medical Officer
Multiple Myeloma Research Consortium
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0213
Fax (203) 972-1259
kelleys@themmrf.org

Joan Levy, PhD

Associate Director of Research
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0233
Fax (203) 972-1259
levyj@themmrf.org



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Lance Armstrong
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemire
Brian Williams
Paula Zahn

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Frederick H. Joseph
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

PARTICIPANT LIST – MMRF/MMRC (CONT)

Anne Quinn Young, MPH
Program Director
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 652-0212
Fax (203) 972-1259
quinnyounga@themmrf.org

Daniel Auclair, PhD
Scientific Consultant
Multiple Myeloma Research Consortium
150 Pheasant Dr
Middletown, CT 06457
Phone (860) 510-3142
Fax (860) 704-0649
auclaird@themmrc.org

Theresa M. Lyons, MS, MS, PhD
Development Manager
Multiple Myeloma Research Foundation
383 Main Ave
Fifth Floor
Norwalk, CT 06851
Phone (203) 229-0206
Fax (203) 972-1259
lyonst@themmrf.org

PARTICIPANT LIST – AOI COMMUNICATIONS, L.P.

Thomas J. Burke
President
AOI Communications, L.P.
415 Eagleview Blvd, Ste 110
Exton, PA 19341
Phone (610) 321-1623 ext 11
Fax (610) 458-1565
tburke@aoic.net

Michele Kashmere
Meeting Planner
AOI Communications, L.P.
415 Eagleview Blvd, Ste 110
Exton, PA 19341
Phone (570) 339-2523
mkashmere@aoic.net

Michelle DiMichele
Client Service Liaison
AOI Communications, L.P.
415 Eagleview Blvd, Ste 110
Exton, PA 19341
Phone (610) 321-1623 ext 17
Fax (610) 458-1565
mdimichele@aoic.net

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D.
Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P.
Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D.
Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

2009 SCIENTIFIC AGENDA ROUNDTABLE

Sponsored by the MMRF and the MMRC

LE PARKER MERIDIEN • NEW YORK, NY

Tuesday, February 17, 2009

BIOGRAPHIES – PARTICIPANTS

Founder/CEO

Kathy Giusti

COO/Executive Director

Scott T. Santarella

Leadership Council

Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemire
Brian Williams
Paula Zahn

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Kenneth C. Anderson, MD

Dana-Farber Cancer Institute

Harvard Medical School

Dr. Anderson graduated from the Johns Hopkins University School of Medicine, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as Chief of the Division of Hematologic Neoplasia, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He serves as Chair of the National Comprehensive Cancer Network (NCCN) Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B principal investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; on the Board of Directors and Chair of the Scientific Advisory Board of the Multiple Myeloma Research Foundation (MMRF); as well as on the Board of Directors and Chair of the Steering Committee of the Multiple Myeloma Research Consortium (MMRC). He has published more than 350 original articles, 250 chapters, and has edited multiple textbooks on both multiple myeloma and on transfusion medicine. He is a Doris Duke Distinguished Clinical Research Scientist and has had long-term R01, P01, and SPORE National Institutes of Health (NIH) funding. His numerous awards include the 2001 Charles C. Lund Award of the American Red Cross Blood Services, the 2003 Waldenström's award for research in plasma cell dyscrasias, the 2004 Johnson & Johnson Focused Giving Award for Setting New Directions in Science and Technology, the 2005 Robert A. Kyle Lifetime Achievement Award, the 2007 American Association for Cancer Research Joseph H. Burchenal Award for Clinical Research, the 2007 ROFEH Distinguished Service Award for providing compassionate patient care internationally, and a 2007 Champion in Advocacy Award from the American Society of Hematology (ASH). He was named Editor in Chief of *Clinical Cancer Research* in 2007. In 2008, he received the Dameshek Prize for Outstanding Contributions to Hematology from ASH and the Celgene Award for Career Achievements in Clinical Hematology.

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

Kenneth C. Anderson, MD (CONT)

*Dana-Farber Cancer Institute
Harvard Medical School*

Over the last two decades, he has focused his translational research studies on B-cell malignancies, especially multiple myeloma. Highlights of his contributions to science and medicine include: discovery of the first plasma cell reactive monoclonal antibodies; development of an immunophenotyping model for diagnosis and treatment of B-cell malignancies; pioneering novel methods to improve safety and efficacy of autografting and allografting in myeloma; characterizing the signaling cascades whereby cytokines mediate myeloma cell growth, survival, and drug resistance in the bone marrow microenvironment; using oncogenomics and developing *in vitro* and *in vivo* models to both identify novel targets and validate therapies targeting the myeloma cell and its bone marrow milieu; translating these preclinical studies to the bedside in derived phase I–III clinical trials; and establishing a new treatment paradigm using novel therapies targeting the tumor cell, tumor-host bone marrow interaction, and bone marrow microenvironment to overcome drug resistance and improve patient outcome in myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as the immunomodulatory drug lenalidomide, culminating in the rapid US Food and Drug Administration (FDA) approval of these agents for treatment of myeloma. His paradigm for identifying and validating targets in the tumor cell and its milieu has therefore already provided novel therapies which have transformed myeloma therapy, and offers great promise to improve patient outcomes in hematologic malignancies and solid tumors as well.

Bart Barlogie, MD, PhD

University of Arkansas for Medical Sciences

Dr. Barlogie is the Director of the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS), and he earned his postgraduate degrees at Heidelberg University and the Max Planck Institute for Medical Research in Germany. Following residency at the universities of Munich and Muenster, he went to MD Anderson Hospital and Tumor Research Institute as a fellow under Dr. Emil J. Freireich. Since joining UAMS in 1989, Dr. Barlogie has created a world-renowned program for multiple myeloma research and therapy, with a focus on "Growth Control in Multiple Myeloma," supported continually for the past 15 years through a P01 grant from the National Cancer Institute (NCI).



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

BIOGRAPHIES – PARTICIPANTS (CONT)

Bart Barlogie, MD, PhD (CONT)
University of Arkansas for Medical Sciences

Dr. Barlogie has received numerous awards and honors, including the Jan Waldenström Award in recognition of his pioneering research and clinical accomplishments in 1999. He received the Celgene Career Achievement Award in Hematology Research in 2002, the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation in 2004, and the National Physician of the Year Award for Clinical Excellence from Castle Connolly Medical Ltd. in 2006. Dr. Barlogie holds the Tommy May Chair of Oncology at UAMS.

Dr. Barlogie has published extensively, including more than 520 peer-reviewed journal articles including four in the *New England Journal of Medicine* and 75 book chapters. He currently serves on the editorial boards of ten journals, including *Blood*, *Clinical and Experimental Medicine*, *Clinical Cancer Research*, and *The Oncologist*.

Richard Caprioli, PhD
Vanderbilt University

Dr. Caprioli is the Stanley Cohen Professor of Biochemistry and Director of the Mass Spectrometry Research Center at Vanderbilt University School of Medicine. He is also currently a professor in the departments of Chemistry and Pharmacology at Vanderbilt University. Dr. Caprioli received his BS in 1965 from Columbia University in New York, NY, his PhD in 1969 in biochemistry, also at Columbia University with Professor David Rittenberg. He did a one-year postdoctoral fellowship at Purdue University with Professor John H. Beynon. In 1970, he was appointed as an assistant professor of biochemistry at Purdue. In 1975, Dr. Caprioli moved to The University of Texas Medical School in Houston where he was professor of biochemistry and molecular biology and Director of the Analytical Chemistry Center until his move to Nashville in early 1998.

Dr. Caprioli is interested in the use of mass spectrometry for the analysis of compounds in biological systems. His current work includes the use of electrospray and laser desorption ionization methods with biological tissues and samples. Applications have focused on the development of this instrumentation and associated methodologies to achieve ultra-high sensitivity detection of endogenous compounds (eg, neuropeptides) in live animal systems. Recent work involves the development of imaging mass spectrometry, a technique whereby

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

Richard Caprioli, PhD (CONT)

Vanderbilt University

molecular images of peptides, proteins, drugs, and other compounds are localized in tissue sections with molecular weight specificity. This method involves molecular mapping of animal tissue through the production of ion images obtained from the analysis of mammalian tissue. Applications to specific research areas involve questions about certain spatial distributions of molecules within specific tissues, eg, mapping proteins in cancer tissue. Specific applications include human glioblastomas, breast cancer, colorectal cancer, and lung cancer.

Dr. Caprioli has been a member of the American Society for Mass Spectrometry since 1975; he served two years each as President of the Society and Vice President for Programs. He is a member of the American Society for Biochemistry and Molecular Biology, the American Association for Cancer Research, and the American Chemical Society. Professor Caprioli has been the Editor in Chief of the *Journal of Mass Spectrometry* since 1990. He is currently coediting several volumes and is a series editor of *Encyclopedia of Mass Spectrometry*. He has published more than 300 scientific papers, and three books. He holds more than ten patents in scientific achievement. In 2003, Dr. Caprioli received the Thomson Medal Award from the International Mass Spectrometry Society "for outstanding achievements in mass spectrometry and for distinguished service to international mass spectrometry." Dr. Caprioli is currently serving a three-year term on the Board of Directors of the Human Proteasome Organisation (HUPO) organization and has been a member of the Board of Directors of the US HUPO since its inception. He received the Field and Franklin Award from the American Chemical Society in April 2006 for Outstanding Achievement in Mass Spectrometry. He has been named as one of the "Pioneers in Proteomics" by the NIH.

Frank L. Douglas, PhD, MD

Kauffman Foundation

Dr. Douglas advises the Kauffman Foundation as a senior fellow. He is a partner of Pure Tech Ventures and the Founder and first Executive Director of the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation. At MIT, he was the professor of the practice in the MIT Sloan School of Management and also held appointments in the Departments of Biology, Biological Engineering, and the Harvard-MIT Division of Health Sciences and Technology. Formerly, Dr. Douglas was Executive Vice President, Chief Scientific Officer, and a member of the Board of Management of Aventis, where he headed drug innovation and approval, with global responsibilities for research, development, and regulatory and marketing support. A leader in innovation in pharmaceutical research and



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

BIOGRAPHIES – PARTICIPANTS (CONT)

Frank L. Douglas, PhD, MD (CONT) *Kauffman Foundation*

development, he serves on the board of directors of a number of biotechnology companies. Dr. Douglas is the recipient of the 2007 Black History Makers Award and has been honored twice as the Global Pharmaceutical R&D Director of the Year. He has also received the Medal of Honor and an honorary professorship from the Johann Wolfgang von Goethe University, Frankfurt, Germany. Dr. Douglas holds a PhD in physical chemistry and MD from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins University School of Medicine and a fellowship in neuroendocrinology at the NIH.

Founder/CEO

Kathy Giusti

COO/Executive Director

Scott T. Santarella

Leadership Council

Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottliemyre
Brian Williams
Paula Zahn

Nicholas C. Dracopoli, PhD

Centocor R&D, Johnson & Johnson

Dr. Dracopoli is Vice President of Biomarkers at Centocor R&D, Johnson & Johnson. In this role, he is responsible for biomarker discovery, development, and application for immunology and oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr. Dracopoli obtained his BSc and PhD degrees from the University of London, and completed postdoctoral fellowships at the Memorial Sloan-Kettering Cancer Center and MIT. Subsequently, he served as an assistant director at the Whitehead/MIT Genome Center, and as a section chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr. Dracopoli has authored more than 70 scientific publications, and he has extensive experience in the fields of genomics, molecular biology, and cancer research.

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Dixie-Lee Esseltine, MD, FRCPC

Millennium: The Takeda Oncology Company

Dr. Esseltine is the Vice President for Global Medical Affairs at Millennium Pharmaceuticals, Inc., in Cambridge, MA. She has been involved with the VELCADE® (bortezomib) development program from phase I through launch, approval, and postmarketing.

Dr. Esseltine received both her BA in zoology and her medical degree at the University of Western Ontario in London, Canada. She did her postgraduate training in internal medicine and hematology at McGill University Hospitals in Montreal, Canada, and in adult oncology at Albany Medical College in Albany, NY.

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

Dixie-Lee Esseltine, MD, FRCPC (CONT)

Millennium: The Takeda Oncology Company

Dr. Esseltine was Assistant Director of Hematology at Montreal Children's Hospital for 12 years and an associate professor at McGill University Department of Pediatrics and the McGill Cancer Center.

She is a fellow of the Royal College of Physicians of Canada (in internal medicine), is certified in hematology (in the province of Quebec, Canada), and American Board Certified in internal medicine.

Dr. Esseltine began her industry career as an associate director for clinical research with the Johnson & Johnson Pharmaceutical Research Institute in Toronto, Canada, in 1990, and has held senior positions subsequently at three companies prior to joining Millennium Pharmaceuticals, Inc.

Ellen G. Feigal, MD

Amgen, Inc.

Dr. Feigal is Executive Medical Director, Global Development, Amgen, Inc. Prior to joining Amgen in 2008, she worked in clinical research and drug development in positions within the federal government, non-profit and for-profit institutes and companies. She was Chief Medical Officer, Insys Therapeutics from 2007 to 2008, Director of Medical Devices and Imaging at the Critical Path Institute, and Vice President of Clinical Sciences and Deputy Scientific Director at the Translational Genomics Research Institute from 2004 to 2007. She directed the NCI's Division of Cancer Treatment and Diagnosis from 2001 to 2004, served as Deputy Director from 1997 through 2001, and served as a senior investigator in the Cancer Therapy Evaluation Program, NCI from 1992 to 1997. Dr. Feigal earned a BS in biology and a MS in molecular biology and biochemistry from the University of California, Irvine, and her MD from the University of California, Davis (UCD). She completed her residency in internal medicine at Stanford University, and her fellowship in hematology/oncology at the University of California, San Francisco (UCSF). She was on the faculty at the UCSF, and University of California, San Diego (UCSD) before joining the NCI. Dr. Feigal is a member of the research faculty in the colleges of Medicine and Pharmacy at the University of Arizona, in the College of Life Sciences at Arizona State University and is adjunct professor and founding Director of the American Course on Drug Development and Regulatory Sciences, UCSF School of Pharmacy.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

BIOGRAPHIES – PARTICIPANTS (CONT)

Carl June, MD
University of Pennsylvania

Dr. June received his BS in chemistry from the United States Naval Academy and his MD from Baylor College of Medicine. He was a research fellow at the World Health Organization Immunology Research and Training Center, Geneva, Switzerland, a resident in internal medicine at the National Naval Medical Center, Bethesda, MD. He was a fellow in oncology at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, where he did postdoctoral research with Dr. Paul Martin and Dr. John Hansen from 1983 to 1986. From 1986 to 1999, Dr. June was at the Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, where he was promoted to the rank of professor in 1995. Since 1999, Dr. June has been at the University of Pennsylvania where currently he is Director of Translational Research Programs and a professor in the Department of Pathology and Laboratory Medicine. Dr. June has authored more than 200 scientific papers and book chapters. His research interests are in the area of lymphocyte biology and adoptive immunotherapy for cancer and infectious diseases.

Jonathan Keats, PhD
Mayo Clinic

Dr. Keats has been actively involved in the myeloma research community for more than ten years. He has authored more than 17 papers and received 15 awards in recognition of his work. His initial work as a PhD student in the laboratory of Dr. Linda Pilarski helped establish the clinical significance of the t(4;14) in myeloma and the target gene of this event. After completing his PhD, he moved to join the newly formed myeloma group at the Mayo Clinic in Arizona headed by Dr. Leif Bergsagel, Dr. Rafael Fonseca, and Dr. Keith Stewart. His work using DNA microarrays resulted in the identification of a series of genetic alterations that result in the constitutive activation of the NF-κB pathways in at least 20% of myeloma patients. His primary research interest is the identification of novel genetic events associated with the development of multiple myeloma or the acquisition of therapeutic resistance.

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D.
Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P.
Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D.
Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

William Matsui, MD

Johns Hopkins University School of Medicine

Dr. Matsui joined the faculty in the Department of Oncology at the Johns Hopkins University School of Medicine in 2002 and is currently an associate professor. He received his medical degree from UCSF in 1995, and completed his residency training in internal medicine at the University of Washington in Seattle. He completed his clinical training in medical oncology at Johns Hopkins. The primary focus of Dr. Matsui's laboratory is studying cancer stem cells. His clinical interests include the development of novel anticancer strategies and bone marrow transplantation.

Mark Miglarese, PhD

OSI Pharmaceuticals, Inc.

Dr. Miglarese heads the Translational Research Department of OSI Oncology Research, bridging preclinical and clinical research efforts within OSI Oncology. He is responsible for translational research activities both in the Boulder and Farmingdale sites. Prior to joining OSI, Dr. Miglarese built the Translational Research Group at Array BioPharma. Prior to Array, Dr. Miglarese worked for several years in cancer drug discovery at Bayer HealthCare Pharmaceuticals, where he assumed increasing responsibility, ultimately holding the position of Section Head in Cancer Biology where he was responsible for pharmacology laboratories and strategic portfolio management for late-stage discovery projects moving into clinical development. Dr. Miglarese received his BS in biology from Virginia Tech and earned his PhD from the University of Virginia studying the regulation of oncogenic transcription factors by phosphorylation. Dr. Miglarese continued his postdoctoral training in cancer drug discovery at Pfizer Central Research and in the Department of Dermatology at Yale University School of Medicine.

Constantine S. Mitsiades, MD, PhD

Dana-Farber Cancer Institute

Harvard Medical School

Dr. Mitsiades received his MD from the University of Athens School of Medicine, where he also received a master's degree in basic and clinical medical sciences and a doctoral degree. He has also received a master's degree in medical sciences from Harvard Medical School. He is currently an instructor in medicine in the Department of Medical Oncology at the Dana-Farber



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

BIOGRAPHIES – PARTICIPANTS (CONT)

Constantine S. Mitsiades, MD, PhD (CONT)
Dana-Farber Cancer Institute
Harvard Medical School

Cancer Institute and the Department of Medicine of the Brigham and Women's Hospital, at Harvard Medical School.

The primary research interest of Dr. Mitsiades is the preclinical and clinical development of novel therapeutic strategies for multiple myeloma and how intrinsic- and microenvironment-dependent mechanisms modulate the responsiveness of tumor cells to therapies. His research has provided the rationale for clinical development of several bortezomib- and lenalidomide-based combination therapies and other emerging classes of anti-myeloma therapies.

Founder/CEO

Kathy Giusti

COO/Executive Director

Scott T. Santarella

Leadership Council

Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

David Parkinson, MD
Nodality

Dr. Parkinson is President and Chief Executive Officer of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision making. Until October 2007, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. At Biogen Idec, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously, he had served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec® (imatinib), Femara® (letrozole), Zometa® (zoledronic acid), Kepivance® (palifermin), and Vectibix® (panitumumab).

Dr. Parkinson worked at the NCI from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. He has also held academic positions at The University of Texas MD Anderson Cancer Center, and New England Medical Center of Tufts University School of Medicine.

He received his MD as gold medalist from the University of Toronto Faculty of Medicine in 1977, with internal medicine and hematology/oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He is a past President of the International Society of Biological Therapy, and past editor of the *Journal of*

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

David Parkinson, MD (CONT)

Nodality

Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine, is a member of the FDA's Science Board and also serves as co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. He was recently elected to the Board of Directors of the American Association for Cancer Research (AACR), and continues to serve as chairman of the AACR Finance Committee.

Deborah Ricci, PhD

Johnson & Johnson

Dr. Ricci was awarded a PhD in genetics from the University of California in 1994. The focus of her dissertation was in describing the regulation of gene expression by antisense RNA cassettes *in vivo* in transgenic mice. Subsequently, the focus of her postdoctoral fellowship, in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, was instrumental in understanding the mechanism of antisense oligodeoxynucleotide action *in vivo* in human subjects admitted to gene therapy clinical trials. She joined Bristol-Myers Squibb in 1999 and was most recently the group leader of the Sample Bank and Molecular Biology laboratory at the Clinical Laboratory of Bristol-Myers Squibb. Dr. Ricci joined Johnson & Johnson PRD in 2004 and is currently a director in the Oncology Biomarkers group responsible for the development, implementation, and execution of biomarker strategies in full development clinical trial. Notably, she was responsible for leading the biomarker-related activities for Velcade® (bortezomib) and chairing the joint J&J and Millennium biomarker project working group.

G. David Roodman, MD, PhD

University of Pittsburgh

Dr. Roodman received a medical degree from the University of Kentucky College of Medicine and a doctorate in biochemistry from the University of Kentucky. His postdoctoral training included an internship in internal medicine at the University of Kentucky, as well as a residency in medicine and a hematology fellowship at the University of Minnesota. Dr. Roodman currently serves as Director of the Myeloma Program at the University of Pittsburgh Cancer Institute and Vice Chair for Research in the University of Pittsburgh School of Medicine's Department of Medicine.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmr.org
www.multiplemyeloma.org

BIOGRAPHIES – PARTICIPANTS (CONT)

G. David Roodman, MD, PhD (CONT) *University of Pittsburgh*

An American Board of Internal Medicine diplomate in internal medicine and hematology, and a diplomate of the National Board of Medical Examiners (NBME), Dr. Roodman holds membership in numerous professional societies and holds positions of prominence with several advisory and regulatory bodies, including Chair of the Paget Foundation. Among Dr. Roodman's many awards are the 2007 Louis V. Avioli Founders Award for Basic Research in Bone and the 2002 John B. Johnson Award for Research in Paget's Disease.

Dr. Roodman is well published in the peer-reviewed literature and is on the editorial boards of several journals, including *Experimental Biology and Medicine* and *Journal of Clinical Investigation*. Additionally, he was an associate editor of *Journal of Bone and Mineral Research*. Dr. Roodman's research focuses on the cellular and molecular events that control the formation and activity of osteoclasts in normal and pathologic states, and he is a highly sought lecturer on these topics. He holds two investigator-initiated NIH grants and heads a Program Project Grant to investigate the role of measles virus in the pathophysiology of Paget's disease and the role that genetics plays in the pathologic process. His research on myeloma bone disease is also funded by The Department of Veterans Affairs Merit Review Grant and the MMRF's Collaborative Program Grant.

Nancy Simonian, MD *Millennium Pharmaceuticals, Inc.*

Dr. Simonian is the Chief Medical Officer at Millennium: The Takeda Oncology Company, which is focused on innovative cancer medicines. She is responsible for Clinical Development, Regulatory Affairs, Pharmacovigilance, and Development Project and Portfolio Management. Dr. Simonian is a member of the executive management team of Millennium and chairs the company's Portfolio Review Committee. She is a member of the board of Arquele Pharmaceuticals, Inc., and the Personalized Medicine Coalition.

Prior to joining Millennium, Dr. Simonian was a vice president of clinical research at Biogen where she was responsible for the clinical development of AVONEX® (interferon β-1a), Tysabri® (natalizumab), and their oncology programs.

Founder/CEO Kathy Giusti

COO/Executive Director Scott T. Santarella

Leadership Council Lester B. Knight Philip J. Purcell Robert Wolf

Honorary Board Dusty Baker Don Baylor Bob Costas Katie Couric Cindy Crawford Ann Curry Geraldine Ferraro Scott Hamilton Mariska Hargitay Bonnie Hunt Senator Kay Bailey Hutchison Dan Jansen Hamilton Jordan Diana Krall Eric McCormack Keith Olbermann Sharon Osbourne Deborah Norville General Norman Schwarzkopf Mel Stottlemyre Brian Williams Paula Zahn

Board of Directors Dana LaForge, Chairman Kenneth C. Anderson, M.D. Karen Andrews Robert J. Beall, Ph.D. Robert B. DeBaun Mark Fishman Kathy Giusti Stephen Grand Alan L. Heller Joseph M. Hogan Anthony K. Kesman Thomas J. Kipps, M.D. Lori Marcus Gerald McDougall William S. McKiernan Charles B. Ortner Alan Panzer Edward Jay Phillips Stuart Rosow William Wilson III Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

Nancy Simonian, MD (CONT)

Millennium Pharmaceuticals, Inc.

She is a graduate of Princeton University and received her MD from the University of Pennsylvania School of Medicine. She did her internship in medicine and residency in neurology at the Massachusetts General Hospital (MGH) and was an assistant clinical professor at MGH and at Harvard Medical School prior to joining industry.

Freda Stevenson, DPhil

University of Southampton

Prof. Stevenson, MSc, DPhil, FRCPath, FMedSci, is a professor of immunology in the School of Medicine at the University of Southampton, UK. She obtained a DPhil from the University of Oxford and is a fellow of the Royal College of Pathologists. She is also an elected fellow of the Academy of Medical Sciences, which includes the leaders in medical science in the UK. She has had a long interest in cancer vaccines, starting with B-cell lymphomas and now extending to solid tumors. Her team has developed a range of novel DNA fusion gene vaccines able to induce specific immune responses in preclinical and clinical settings.

Her expertise in analysis of immunoglobulin genes has facilitated investigation of the pattern of these genes in B-cell tumors relevant for the pathogenesis and progression of myeloma, lymphomas, and leukemias. In 1999, she published a paper, identified in the Focus on Hematology section of *Blood*, which described how the Ig gene status in cases of chronic lymphocytic leukemia acts as a major prognostic factor. The findings are having a significant impact on the management and understanding of this disease.

Prof. Stevenson has published widely in major immunological and hematological journals, and is a regular reviewer for many. She is an associate editor of the *Journal of Immunology* and of *Haematologica*. She is a member of several scientific advisory groups, including the MMRF and the Committee for the Immunotherapy of Cancer, and she is a visiting professor at the Johannes Gutenberg University in Mainz, Germany. She is an invited symposium speaker at more than ten international conferences each year.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemire
Brian Williams
Paula Zahn

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

BIOGRAPHIES – PARTICIPANTS (CONT)

Michael Tomasson, MD
Washington University

Dr. Tomasson graduated from Stanford University, trained in internal medicine at Stanford, and completed a fellowship in hematology/oncology at Massachusetts General Hospital. He is currently the scientific director for the Siteman Cancer Center Myeloma Program and an assistant professor of medicine and genetics at Washington University in St. Louis, MO. Dr. Tomasson served as a Leukemia Society of America fellow from 1998 to 2000 and has received several awards for his research including the 1997 Lori Strauss Leukemia Foundation Award, a 2004 Translational Research Award from The Leukemia & Lymphoma Society (LLS), and the 2007 Hope Award from the American Cancer Society (ACS). He has published more than 30 original articles and serves as a reviewer for *Blood*, *Cancer Cell*, *Oncogene*, *Leukemia*, and *Stem Cells*. Dr. Tomasson's research focuses on the pathogenesis of hematopoietic malignancies, in particular acute myeloid leukemia and multiple myeloma.

Richard L. Wahl, MD
Johns Hopkins Medicine

Dr. Wahl is the Director of Nuclear Medicine, Vice Chair of New Technology and Business Development in the Russell H. Morgan Department of Radiology and Radiological Science. He is Professor of Radiology, Oncology and the Henry N. Wagner Jr, MD, Professor of Nuclear Medicine.

Dr. Wahl was one of the first in the world to recognize and prove the utility of positron emission tomography (PET) imaging for visceral cancers. He and his colleagues demonstrated that PET could accurately diagnose breast cancer, melanoma, and ovarian cancer, and that it was superior to computed tomography (CT) in staging lung cancer. He and his colleagues were the first to show PET could monitor and predict the response of cancer therapy. Dr. Wahl has helped translate the PET "metabolic biopsy" into clinical practice for a diverse array of human cancers. He and colleagues developed PET/CT fusion imaging and at Johns Hopkins helped develop the clinical applications of PET/CT imaging.

In the area of cancer treatment, Dr. Wahl has worked more than 25 years to develop patient-specific "smart radiopharmaceuticals," those that treat and target tumors, not normal tissue. He is an inventor of radioimmunotherapy for non-Hodgkin lymphoma, holding multiple patents on a number of such new FDA-approved therapeutics.

Dr. Wahl graduated *summa cum laude* in chemistry from Wartburg College in Waverly, IA. He received his medical degree from Washington University in St. Louis, and completed his

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – PARTICIPANTS (CONT)

Richard L. Wahl, MD (CONT)

Johns Hopkins Medicine

internship at UCSD. Dr. Wahl returned to St. Louis and Washington University to perform his residency in diagnostic radiology at the Mallinckrodt Institute of Radiology. He also concurrently completed two fellowships there: one in nuclear medicine at the Mallinckrodt Institute; the second in immunology research at the Howard Hughes Medical Institute. He is board certified in diagnostic radiology and nuclear medicine, with special competency certification in nuclear radiology.

Dr. Wahl joined the faculty at the University of Michigan in 1983 as an assistant professor of medicine and radiology and codirector of nuclear imaging. In 1987, he became an associate professor and director of nuclear imaging. In 1990, he was promoted to professor of internal medicine and radiology; and in 1996, he founded and directed the radiopharmaceutical program of the University of Michigan Comprehensive Cancer Center. In September 2000, he joined the faculty of Johns Hopkins.

Dr. Wahl has published more than 325 journal articles, 30 book chapters, and five books; has been an invited lecturer at more than 600 conferences worldwide; serves on the editorial boards of four scientific journals; is a reviewer for more than a dozen government services, including the NIH, the NCI and the Department of Energy; and holds 15 patents. His honors and awards include life memberships on the American Board of Nuclear Medicine (Chairman, 1998) and the Experimental Immunology Study Section of the NIH (1990–94); listings in the *Best Doctors in America* and *Who's Who in America and the World*; service as President of the Institute for Clinical PET (1995–96); and duties as plenary lecturer at many international conferences, including the Marie Curie Plenary Lecturer at the European Association of Nuclear Medicine in 1998. He also delivered the "New Horizons Lecture" at the 1999 meeting of the Radiological Society of North America. He received the "Distinguished Scientist" award for 2001 from the Academy of Molecular Imaging. He has recently delivered plenary lectures to the European Society of Nuclear Medicine, Japanese Society of Nuclear Medicine, and The Japanese Radiological Society.

His current research focuses on optimizing the use of PET/CT in personalizing cancer therapies as well as developing new treatments for a range of cancers with targeted radiopharmaceuticals.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

Founder/CEO
Kathy Giusti

COO/Executive Director
Scott T. Santarella

Leadership Council
Lester B. Knight
Phillip J. Purcell
Robert Wolf

Honorary Board
Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors
Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

BIOGRAPHIES – PARTICIPANTS (CONT)

Jeffrey Wolf, MD
University of California, San Francisco

Dr. Wolf is an expert in cancer of the bone marrow and blood as well as an expert in bone marrow transplantation to treat these cancers. His primary area of research is myeloma, the second most common cancer of the blood. He is the Director of the Myeloma Program and Clinical Research Director of Hematologic Malignancies, at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Wolf earned a medical degree at the University of Illinois in Chicago and completed a residency in medicine at UCSD. He completed a hematology and oncology fellowship at UCSF and a bone marrow transplantation rotation at the Fred Hutchinson Cancer Center in Seattle. He helped establish the bone marrow transplant program at the City of Hope National Medical Center in Duarte, CA, in 1979, and the first community hospital-based bone marrow transplant unit at Alta Bates Medical Center in Berkeley in 1984. Dr. Wolf joined the UCSF Division of Hematology and Oncology in February 2007, and is a clinical professor of medicine at UCSF.

Jerry Zeldis, MD, PhD
Celgene Corporation

Dr. Zeldis is Senior Vice President of Clinical Research and Medical Affairs and Chief Medical Officer of Celgene Corporation in Summit, NJ. He attended Brown University for an AB, MS, followed by Yale University for an MPhil, MD, PhD, in molecular biophysics and biochemistry (immunochemistry). Dr. Zeldis trained in internal medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was assistant professor of medicine at Harvard Medical School, associate professor of medicine at UCD, clinical associate professor of medicine at Cornell Medical School, and professor of clinical medicine at UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, NJ chapter of the Arthritis Foundation, and the Castleman's Disease Organization. He has published 100 peer-reviewed articles and 24 reviews, book chapters, and editorials.

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – MMRF/MMRC

Kathy Giusti

Multiple Myeloma Research Foundation

Multiple Myeloma Research Consortium

Kathy Giusti is the Founder and Chief Executive Officer of the *Multiple Myeloma Research Foundation* (MMRF) and the *Multiple Myeloma Research Consortium* (MMRC). In 1998, following her diagnosis with multiple myeloma, Ms. Giusti founded the MMRF to fund innovative myeloma research and drug discovery. Having raised more than \$100 million to date, the MMRF is the world's number one funder of myeloma research. As an extension of the MMRF's mission, Ms. Giusti founded the MMRC in 2004 to enable leading research institutions to work with industry to speed the discovery and development of effective new treatments. Comprising 14 academic institutions across North America, the MMRC is widely recognized for breaking down barriers in tissue banking, data management, genomics, and clinical trials, and is considered an optimal research model to accelerate the development of new therapies. To date, the MMRC has advanced 17 clinical trials of novel compounds and combination approaches through its clinical trials network. Ms. Giusti received her MBA in general management from Harvard Business School and graduated from the University of Vermont magna cum laude with a BS in biological sciences. She began her career in 1980 with Merck & Co., and later joined the Gillette Company. In 1993, she joined G.D. Searle & Co., where she last served as Executive Director of Searle's worldwide arthritis franchise. Ms. Giusti received the 1998 Healthcare Businesswomen's Association's Woman of the Year Award, the 2001 Harvard Business School Entrepreneurial Award, the 2002 McCarty Cancer Foundation Humanitarian Award, the 2002 Joseph Michaela Award from the Weill Medical College of Cornell University, the 2005 Harvard Business School Award for Courage and Valor, the 2006 Partners in Progress Award from the American Society of Clinical Oncology, and the 2009 Centennial Medal for Distinguished Public Service from the American Association for Cancer Research. She has served on the Institute of Medicine's National Cancer Policy Board and the Cancer Leadership Council. Today, she continues to serve on the National Cancer Advisory Board, an appointment she received in 2003 from President Bush, and is a member of the Board of Directors for IMS Health as well as the Health Research Alliance. Most recently, her efforts to advance cancer research and drug development have been featured in *The Wall Street Journal* and *The New Yorker* and on *CNBC*, *NBC Nightly News*, and *CBS Evening News*. She lives in New Canaan, CT with her husband, Paul, and her children, Nicole, who is 14, and David, who is 12.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

BIOGRAPHIES – MMRF/MMRC (CONT)

Susan Kelley, MD *Multiple Myeloma Research Consortium*

Susan L. Kelley, MD, is Chief Medical Officer of the MMRC, where she provides senior medical leadership for the clinical development activities supported by the MMRC.

Dr. Kelley has more than 20 years of experience in oncology clinical research and drug development within the pharmaceutical industry. Dr. Kelley most recently served as Vice President and head of Global Oncology Clinical Development at Bayer Healthcare Pharmaceuticals, where she was responsible for the worldwide management of the oncology drug development portfolio and for management of Bayer's oncology physicians and clinical project managers. While at Bayer, she oversaw the successful advance of Nexavar® (sorafenib) through phase III clinical trials and the FDA approval process. Prior to her position at Bayer, Dr. Kelley held several leadership positions in Bristol-Myers Squibb (BMS) Oncology Clinical Development. While at BMS, she participated in the development and registration of several new drug products, including Vumon® (teniposide), Taxol® (paclitaxel), and Videx® (didanosine); she also supervised clinical development programs for a cancer vaccine for melanoma and numerous phase I and II clinical trials.

Dr. Kelley received her medical degree from Duke University School of Medicine. She completed certification in internal medicine at the University of Colorado followed by medical oncology training at the Dana-Farber Cancer Institute in Boston. Prior to joining the pharmaceutical industry, Dr. Kelley has been a faculty member involved in clinical and laboratory research in oncology at Yale University School of Medicine.

Louise M. Perkins, PhD *Multiple Myeloma Research Foundation*

Louise M. Perkins, PhD, is the Chief Scientific Officer at the MMRF, where she is responsible for the strategic development and execution of the MMRF's research agenda. Dr. Perkins brings more than 16 years of pharmaceutical research experience from two major companies to the MMRF.

Prior to joining the MMRF, she was Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar® and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a

Founder/CEO

Kathy Giusti

COO/Executive Director

Scott T. Santarella

Leadership Council

Lester B. Knight
Philip J. Purcell
Robert Wolf

Honorary Board

Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottliemyre
Brian Williams
Paula Zahn

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D.
Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P.
Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D.
Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – MMRF/MMRC (CONT)

Louise M. Perkins, PhD (CONT)

Multiple Myeloma Research Foundation

cancer research group at the Schering-Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data.

Dr. Perkins graduated from the University of Michigan with a PhD and MS in biological chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in zoology from the University of North Carolina at Chapel Hill.

Joan Levy, PhD

Multiple Myeloma Research Foundation

Joan Levy, PhD, is the Associate Director of Research at the MMRF, where she is responsible for the planning and implementation of its research agenda. Dr. Levy has more than 20 years of experience in oncology and osteoporosis research in both pharmaceutical and academic settings.

Before joining the MMRF, Dr. Levy was Technical Director at The Binding Site, supporting use of Freelite™, a diagnostic assay for multiple myeloma. In addition, she worked at Bayer Pharmaceuticals Corporation in West Haven, CT, for nine years. In that capacity, she was engaged in target identification, compound validation, and project leadership in the fields of cancer and osteoporosis research. She has contributed to the delivery of novel drug candidates for clinical studies in each of these indications.

Dr. Levy earned her PhD at the University of Vermont and then completed two postdoctoral fellowships at the Rockefeller University and later at the State University of New York at Stony Brook. Her two academic appointments were at New York University Medical Center and Yale University, studying various aspects of cell signaling pathways involved in the pathogenesis of cancer and development of osteoporosis.



MMRF

Multiple Myeloma
Research Foundation

Funding treatments faster. Finding a cure.



383 Main Avenue
MerrittView – 5th Floor
Norwalk, CT 06851
Ph: (203) 229-0464
Fx: (203) 229-0572
E-mail: info@themmrf.org
www.multiplemyeloma.org

BIOGRAPHIES – MMRF/MMRC (CONT)

Anne Quinn Young, MPH *Multiple Myeloma Research Foundation*

Anne Quinn Young is the Program Director at the MMRF, where she oversees all communications as well as educational programming for and outreach to healthcare professionals and patients. Anne currently serves as the MMRF's representative on the Cancer Leadership Council (CLC) and as principal investigator on a major grant from the Centers for Disease Control and Prevention (CDC).

Prior to joining the MMRF, Ms. Young was a consultant in the healthcare practice of Datamonitor, a global market research and business intelligence company. She previously worked in healthcare public relations at Burson-Marsteller and Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division.

Ms. Young has a master's degree in public health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a BA in government.

Theresa M. Lyons, MS, MS, PhD *Multiple Myeloma Research Foundation*

Theresa M. Lyons, MS, MS, PhD, is the Development Manager at the MMRF, where she is responsible for the expansion of efficient and effective development programs to enhance cultivation and reinvestment of the MMRF annual revenue budget. Prior to joining the MMRF, Dr. Lyons was a medical strategist at 81qd, a healthcare consulting company, in which she was the lead scientific person for new business development, procurement, and various projects consulting on drug life cycle management. She has experience in identifying Key Opinion Leaders (KOLs), physician influence mapping, sentiment analysis, market research, and message mapping. She has worked on projects in numerous therapeutic areas including oncology and immunology. Dr. Lyons received her doctorate in computational chemistry from Yale University and completed her postdoctoral fellowship at sanofi-aventis. She holds a master's degree in synthetic organic chemistry from St. John's University and a master's degree in chemistry from Yale University.

Founder/CEO Kathy Giusti

COO/Executive Director Scott T. Santarella

Leadership Council Lester B. Knight Philip J. Purcell Robert Wolf

Honorary Board

Dusty Baker
Don Baylor
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Geraldine Ferraro
Scott Hamilton
Mariska Hargitay
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hamilton Jordan
Diana Krall
Eric McCormack
Keith Olbermann
Sharon Osbourne
Deborah Norville
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Paula Zahn

Board of Directors

Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
Robert J. Beall, Ph.D.
Robert B. DeBaun
Mark Fishman
Kathy Giusti
Stephen Grand
Alan L. Heller
Joseph M. Hogan
Anthony K. Kesman
Thomas J. Kipps, M.D.
Lori Marcus
Gerald McDougall
William S. McKiernan
Charles B. Ortner
Alan Panzer
Edward Jay Phillips
Stuart Rosow
William Wilson III
Donna Zaccaro

Scientific Advisors

Kenneth C. Anderson, M.D., Chairman

Bart Barlogie, M.D., Ph.D. • William Bensinger, M.D. • James Berenson, M.D. • P. Leif Bergsagel, M.D., F.R.C.P.(C.) • Mario Boccadoro, M.D. • William Dalton, Ph.D., M.D. • Meletios A. Dimopoulos, M.D. • Philip Greipp, M.D. • Jean-Luc Harousseau, M.D. • Mohamad A. Hussein, M.D. • Sundar Jagannath, M.D. • Douglas Joshua, D.Phil., F.R.A.C.P. • Thomas J. Kipps, M.D., Ph.D. • Kenneth Nilsson, M.D., Ph.D. • Steven D. Nimer, M.D. • G. David Roodman, M.D., Ph.D. • Steven Rosen, M.D. • Jesus F. San Miguel, M.D., Ph.D. • Pieter Sonneveld, M.D., Ph.D. • Louis M. Staudt, M.D., Ph.D. • Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P. • A. Keith Stewart, M.B.Ch.B., F.R.C.P.(C.) • Donna M. Weber, M.D.

BIOGRAPHIES – MMRF/MMRC (CONT)

Daniel Auclair, PhD

Multiple Myeloma Research Consortium

Daniel Auclair obtained his PhD in 1997 in Montreal, Canada, where he focused on the involvement of stress proteins and the ubiquitin-proteasome pathway in diseased states, Dr. Auclair completed a postdoctoral fellowship at the Dana-Farber Cancer Institute in Dr. Lan Bo Chen's lab. During his stay at the Dana-Farber, Dr. Auclair used a number of genomic approaches to elucidate the mode of action of novel anticancer drugs and identify new cancer markers. In particular, Dr. Auclair's collaborative efforts with Dr. Ken Anderson produced five publications on multiple myeloma genomics. During this period, Dr. Auclair also worked with local biotechs such as Shionogi BioResearch Corp. (now Synta Pharmaceuticals Corp.) assisting them in implementing their genomic platforms and using it to optimize their lead drug candidates. Dr. Auclair was recruited in 2001 by Bayer HealthCare as project manager of the oncology facet of its genomic collaboration with Millennium Pharmaceuticals. During his six year tenure at Bayer, Dr. Auclair also led a number of drug discovery projects and was a member of the preclinical team for Nexavar®. Since 2007, Dr. Auclair has been working as a scientific consultant for the MMRC, helping it to manage the flagship Multiple Myeloma Genomics Initiative.

